Partnering makes sense from an economic perspecitve.. If Insmed were to partner with a deep-pocket pharma, they could easily initiate a phase III diabetes study, complete the phase II myotonic dystrophy study, and several other studies simultaneously, and not bat an eye.
As it is, there are money constraints to consider before they can move ahead with those important trials.
There is little question that Iplex™ is a far superior drug to Increlex™, and will ultimately take over TRCA's market for severe short status.
The bigger issue is development of drugs for a larger market...(severe short status accounts for only 6K patients in the US presently). Whereas diabetes is rapidly becoming a major health threat to millions worldwide...
Market Data 
Markets 
AI
